CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+ / HER2- metastatic breast cancer

Menarini Silicon Biosystems Italy United States of America Canada France Germany Spain United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/cellsearch-ctc-count-proves-its-clinical-utility-in-guiding-therapeutic-strategy-supporting-patient-care-in-hrher2--metastatic-breast-cancer-302035017.html